火针在肾虚湿热型下尿路症状中的应用
|
摘要
目的:探讨火针对于各种疾病引起肾虚湿热型下尿路症状(LUTS)的治疗价值。方法:选取2016年5月-2017年9月就诊于沈阳红十字会医院的100例LUTS患者,按照随机数字表法将其分为治疗组和对照组,各50例。治疗组给予火针治疗,对照组给予甲磺酸多沙唑嗪缓释片(可多华)治疗。比较两组治疗前后患者的国际前列腺症状评分(I-PSS)、最大及平均尿流率(Qmax)。结果:治疗前、治疗第4周,两组I-PSS评分、Qmax比较,差异均无统计学意义(P>0.05),治疗第4周、治疗后4周,两组I-PSS评分、Qmax均较治疗前改善(P<0.05),且治疗组治疗后4周I-PSS评分、Qmax均优于对照组(P<0.05)。结论:火针对于各种疾病引起的肾虚湿热型LUTS有改善作用,远期疗效优于口服可多华,可以临床推广。
Objective:To explore the therapeutic value of fire needle in treating lower urinary tract symptoms(LUTS)of kidney deficiency and damp heat type caused by various diseases.Method:A total of 100 LUTS patients from May 2016 to September 2017 in Shenyang Red Cross Hospital were selected.According to the random number table method,they were divided into treatment group and control group,50 cases in each group.The treatment group was treated with fire needle,while the control group was treated with Doxazosin Mesylate Sustained-release Tablets(Cardura).The International Prostate Symptom Score(I-PSS),Maximum and Average Urinary Flow Rate(Qmax)were compared between two groups before and after treatment.Result:Before and 4th week of treatment,the I-PSS score and Qmax in two groups were compared,the differences were not statistically significant(P>0.05).The 4th weeks of treatment and after treatment 4 weeks,the I-PSS score and Qmax of two groups were improved compared with those of before treatment(P<0.05),the I-PSS score and Qmax of treatment group were better than those of control group after treatment 4 weeks(P<0.05).Conclusion:Fire needle can improve the LUTS of kidney deficiency and damp heat caused by various diseases,long-term efficacy is superior to oral Cardura,can be clinically promoted.
Objective:To explore the therapeutic value of fire needle in treating lower urinary tract symptoms(LUTS)of kidney deficiency and damp heat type caused by various diseases.Method:A total of 100 LUTS patients from May 2016 to September 2017 in Shenyang Red Cross Hospital were selected.According to the random number table method,they were divided into treatment group and control group,50 cases in each group.The treatment group was treated with fire needle,while the control group was treated with Doxazosin Mesylate Sustained-release Tablets(Cardura).The International Prostate Symptom Score(I-PSS),Maximum and Average Urinary Flow Rate(Qmax)were compared between two groups before and after treatment.Result:Before and 4th week of treatment,the I-PSS score and Qmax in two groups were compared,the differences were not statistically significant(P>0.05).The 4th weeks of treatment and after treatment 4 weeks,the I-PSS score and Qmax of two groups were improved compared with those of before treatment(P<0.05),the I-PSS score and Qmax of treatment group were better than those of control group after treatment 4 weeks(P<0.05).Conclusion:Fire needle can improve the LUTS of kidney deficiency and damp heat caused by various diseases,long-term efficacy is superior to oral Cardura,can be clinically promoted.
引文
[1]中国中西医结合学会男科专业委员会.良性前列腺增生中西医结合诊疗指南(试行版)[J].中华男科学杂志,2017,23(3):280-285.
[2]黄华松,李扬健,郑重,等.下尿路疾病预后与尿动力学检查指标的关系研究[J].湖南师范大学学报(医学版),2017,14(1):136-138.
[3]李浩,米庆辉,高用军,等.前列舒通胶囊联合坦索罗辛对良性前列腺增生患者血清睾酮、雌二醇水平的影响及其临床疗效研究[J].中国生化药物杂志,2015,35(3):89-91.
[4]Zlotta A R,Teillac P,Raynaud J P,et al.Evaluation of male sexual function in patients with lower urinary tract symptoms(LUTS)associated with benign prostatic hyperplasia(BPH)treated with a phytotherapeutic agent(permixon),tamsulosinor finasterid[J].Eur Urol,2005,48(2):269-276.
[5]Mitterberger M,Pallwein L,Gradl J,et al.Persistentdetrusor over activity after transurethral resection of the prostate is associated with reduced perfusion of the urinary bladder[J].BJU Int,2007,99(4):831-835.
[6]lzumi K,Li L,Chang C.Androgen receptor and immune inflammation in benign peostatic hyperplasia and proslate cancer[J].Clin Investig(Lond),2016,4(10):935-950.
[7]贾利民,张晨光,王艳凤.尿动力学检测在前列腺增生患者中的意义[J].中国性科学,2014,23(4):62-64.
[8]Lin-Tsai O,Clark P E,Miller N L,et al.Surgical intervention for symptomatic benign prostatic hyperplasia is correlated wiyh expression of the AP-I transcription factor network[J].Proslate,2014,74(6):669-679.
[9]杨博宇,夏术阶.应高度重视良性前列腺增生症患者的膀胱问题[J].中华医学杂志,2017,97(22):1681-1682.
[10]Kojima Y,Sasaki S,Oda N,et al.Prostate growth inhibition by subtype-selective alpha(1)-adrenoceptor antagonist naftopidil in benign prostatic hyperplasia[J].Prostate,2009,69(14):1521-1528.
[11]曹海东.免疫性炎症与良性前列腺增生[J].国际泌尿系统杂志,2017,37(3):446-448.
[12]李春雨,金龙涛.普通针刺在下尿路症状患者治疗中的应用[J].针灸临床杂志,2015,31(6):11-13.
[13]袁琛,桂定文,王小英,等.索利那新联合坦索罗辛治疗前列腺增生伴下尿路症状患者的疗效观察[J].中国性科学,2017,26(6):10-12.
[14]张翼,刘兴宝.坦索罗辛联合金匮肾气丸治疗前列腺增生伴勃起功能障碍疗效观察[J].中国性医学,2015,24(7):3-5.
[15]李曰庆.中医外科学[M].北京:人民卫生出版社,2015:114-120.
[16]郭晓辉,董洪海,张汝正,等.中药辅助治疗TURP术后下尿路症候群的临床研究[J].内蒙古中医药,2014,33(5):3-4.
[17]彭庆珊,向开维.火针治疗20例强直性脊柱炎临床疗效观察[J].亚太传统医药,2017,13(1):136-137.
[18]包烨华,楚佳梅,李丽萍,等.热敏灸治疗脑卒中后尿失禁的临床研究[J].上海针灸杂志,2016,35(7):786-788.
[19]周倩,高维滨.电针治疗女性压力性尿失禁20例[J].上海针灸杂志,2010,29(2):124.
[20]莫倩,刘志顺.针灸治疗压力性尿失禁的诊疗特点分析[J].上海针灸杂志,2013,32(12):1060-1063.
[2]黄华松,李扬健,郑重,等.下尿路疾病预后与尿动力学检查指标的关系研究[J].湖南师范大学学报(医学版),2017,14(1):136-138.
[3]李浩,米庆辉,高用军,等.前列舒通胶囊联合坦索罗辛对良性前列腺增生患者血清睾酮、雌二醇水平的影响及其临床疗效研究[J].中国生化药物杂志,2015,35(3):89-91.
[4]Zlotta A R,Teillac P,Raynaud J P,et al.Evaluation of male sexual function in patients with lower urinary tract symptoms(LUTS)associated with benign prostatic hyperplasia(BPH)treated with a phytotherapeutic agent(permixon),tamsulosinor finasterid[J].Eur Urol,2005,48(2):269-276.
[5]Mitterberger M,Pallwein L,Gradl J,et al.Persistentdetrusor over activity after transurethral resection of the prostate is associated with reduced perfusion of the urinary bladder[J].BJU Int,2007,99(4):831-835.
[6]lzumi K,Li L,Chang C.Androgen receptor and immune inflammation in benign peostatic hyperplasia and proslate cancer[J].Clin Investig(Lond),2016,4(10):935-950.
[7]贾利民,张晨光,王艳凤.尿动力学检测在前列腺增生患者中的意义[J].中国性科学,2014,23(4):62-64.
[8]Lin-Tsai O,Clark P E,Miller N L,et al.Surgical intervention for symptomatic benign prostatic hyperplasia is correlated wiyh expression of the AP-I transcription factor network[J].Proslate,2014,74(6):669-679.
[9]杨博宇,夏术阶.应高度重视良性前列腺增生症患者的膀胱问题[J].中华医学杂志,2017,97(22):1681-1682.
[10]Kojima Y,Sasaki S,Oda N,et al.Prostate growth inhibition by subtype-selective alpha(1)-adrenoceptor antagonist naftopidil in benign prostatic hyperplasia[J].Prostate,2009,69(14):1521-1528.
[11]曹海东.免疫性炎症与良性前列腺增生[J].国际泌尿系统杂志,2017,37(3):446-448.
[12]李春雨,金龙涛.普通针刺在下尿路症状患者治疗中的应用[J].针灸临床杂志,2015,31(6):11-13.
[13]袁琛,桂定文,王小英,等.索利那新联合坦索罗辛治疗前列腺增生伴下尿路症状患者的疗效观察[J].中国性科学,2017,26(6):10-12.
[14]张翼,刘兴宝.坦索罗辛联合金匮肾气丸治疗前列腺增生伴勃起功能障碍疗效观察[J].中国性医学,2015,24(7):3-5.
[15]李曰庆.中医外科学[M].北京:人民卫生出版社,2015:114-120.
[16]郭晓辉,董洪海,张汝正,等.中药辅助治疗TURP术后下尿路症候群的临床研究[J].内蒙古中医药,2014,33(5):3-4.
[17]彭庆珊,向开维.火针治疗20例强直性脊柱炎临床疗效观察[J].亚太传统医药,2017,13(1):136-137.
[18]包烨华,楚佳梅,李丽萍,等.热敏灸治疗脑卒中后尿失禁的临床研究[J].上海针灸杂志,2016,35(7):786-788.
[19]周倩,高维滨.电针治疗女性压力性尿失禁20例[J].上海针灸杂志,2010,29(2):124.
[20]莫倩,刘志顺.针灸治疗压力性尿失禁的诊疗特点分析[J].上海针灸杂志,2013,32(12):1060-1063.